Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 115

1.

Efficacy of aprepitant among patients aged 65 and over receiving moderately to highly emetogenic chemotherapy: a meta-analysis of unpublished data from previously published studies.

Chapell R, Aapro MS.

J Geriatr Oncol. 2013 Jan;4(1):78-83. doi: 10.1016/j.jgo.2012.08.008. Epub 2012 Sep 15.

PMID:
24071495
[PubMed - indexed for MEDLINE]
2.

Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study.

Rapoport BL, Jordan K, Boice JA, Taylor A, Brown C, Hardwick JS, Carides A, Webb T, Schmoll HJ.

Support Care Cancer. 2010 Apr;18(4):423-31. doi: 10.1007/s00520-009-0680-9. Epub 2009 Jul 1.

PMID:
19568773
[PubMed - indexed for MEDLINE]
3.

Review of the efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in a range of tumor types.

Aapro MS, Schmoll HJ, Jahn F, Carides AD, Webb RT.

Cancer Treat Rev. 2013 Feb;39(1):113-7. doi: 10.1016/j.ctrv.2012.09.002. Epub 2012 Oct 11. Review.

PMID:
23062719
[PubMed - indexed for MEDLINE]
4.

The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.

de Wit R, Herrstedt J, Rapoport B, Carides AD, Guoguang-Ma J, Elmer M, Schmidt C, Evans JK, Horgan KJ.

Eur J Cancer. 2004 Feb;40(3):403-10.

PMID:
14746859
[PubMed - indexed for MEDLINE]
5.

Efficacy and safety of aprepitant in the prevention of chemotherapy-induced nausea and vomiting: a pooled analysis.

Jin Y, Wu X, Guan Y, Gu D, Shen Y, Xu Z, Wei X, Chen J.

Support Care Cancer. 2012 Aug;20(8):1815-22. doi: 10.1007/s00520-011-1280-z. Epub 2011 Oct 5.

PMID:
21971667
[PubMed - indexed for MEDLINE]
6.

Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy.

Grunberg SM, Dugan M, Muss H, Wood M, Burdette-Radoux S, Weisberg T, Siebel M.

Support Care Cancer. 2009 May;17(5):589-94. doi: 10.1007/s00520-008-0535-9. Epub 2008 Nov 27.

PMID:
19037667
[PubMed - indexed for MEDLINE]
7.

Aprepitant: a novel antiemetic for chemotherapy-induced nausea and vomiting.

Massaro AM, Lenz KL.

Ann Pharmacother. 2005 Jan;39(1):77-85. Epub 2004 Nov 23. Review.

PMID:
15562136
[PubMed - indexed for MEDLINE]
8.

The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group.

Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, Chawla SP, Carides AD, Ianus J, Elmer ME, Evans JK, Beck K, Reines S, Horgan KJ; Aprepitant Protocol 052 Study Group.

J Clin Oncol. 2003 Nov 15;21(22):4112-9. Epub 2003 Oct 14.

PMID:
14559886
[PubMed - indexed for MEDLINE]
9.

[A meta-analysis of aprepitant for prevention of chemotherapy-induced nausea and vomiting].

Fang ZW, Zhai SD.

Beijing Da Xue Xue Bao. 2010 Dec 18;42(6):756-63. Chinese.

PMID:
21170111
[PubMed - indexed for MEDLINE]
Free Article
10.

Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.

Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie Ma G, Eldridge K, Hipple A, Evans JK, Horgan KJ, Lawson F; Aprepitant Protocol 054 Study Group.

Cancer. 2003 Jun 15;97(12):3090-8.

PMID:
12784346
[PubMed - indexed for MEDLINE]
Free Article
11.

Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.

Chawla SP, Grunberg SM, Gralla RJ, Hesketh PJ, Rittenberg C, Elmer ME, Schmidt C, Taylor A, Carides AD, Evans JK, Horgan KJ.

Cancer. 2003 May 1;97(9):2290-300.

PMID:
12712486
[PubMed - indexed for MEDLINE]
Free Article
13.

Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy.

de Wit R, Herrstedt J, Rapoport B, Carides AD, Carides G, Elmer M, Schmidt C, Evans JK, Horgan KJ.

J Clin Oncol. 2003 Nov 15;21(22):4105-11. Epub 2003 Oct 14.

PMID:
14559891
[PubMed - indexed for MEDLINE]
14.

A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.

Yeo W, Mo FK, Suen JJ, Ho WM, Chan SL, Lau W, Koh J, Yeung WK, Kwan WH, Lee KK, Mok TS, Poon AN, Lam KC, Hui EK, Zee B.

Breast Cancer Res Treat. 2009 Feb;113(3):529-35. doi: 10.1007/s10549-008-9957-9. Epub 2008 Mar 10.

PMID:
18327706
[PubMed - indexed for MEDLINE]
15.

Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.

Schwartzberg L, Jackson J, Jain G, Balu S, Buchner D.

Expert Rev Pharmacoecon Outcomes Res. 2011 Aug;11(4):481-8. doi: 10.1586/erp.11.47. Epub 2011 Jun 28.

PMID:
21711119
[PubMed - indexed for MEDLINE]
16.

Analysis of aprepitant for prevention of chemotherapy-induced nausea and vomiting with moderately and highly emetogenic chemotherapy.

Molassiotis A, Nguyen AM, Rittenberg CN, Makalinao A, Carides A.

Future Oncol. 2013 Oct;9(10):1443-50. doi: 10.2217/fon.13.155. Epub 2013 Aug 29.

PMID:
23987791
[PubMed - indexed for MEDLINE]
17.

Aprepitant triple therapy for the prevention of chemotherapy-induced nausea and vomiting following high-dose cisplatin in Chinese patients: a randomized, double-blind, placebo-controlled phase III trial.

Hu Z, Cheng Y, Zhang H, Zhou C, Han B, Zhang Y, Huang C, Chang J, Song X, Liang J, Liang H, Bai C, Yu S, Chen J, Wang J, Pan H, Chitkara DK, Hille DA, Zhang L.

Support Care Cancer. 2014 Apr;22(4):979-87. doi: 10.1007/s00520-013-2043-9. Epub 2013 Nov 26.

PMID:
24276953
[PubMed - indexed for MEDLINE]
18.
19.

The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials.

Warr DG, Grunberg SM, Gralla RJ, Hesketh PJ, Roila F, Wit Rd, Carides AD, Taylor A, Evans JK, Horgan KJ.

Eur J Cancer. 2005 Jun;41(9):1278-85.

PMID:
15939263
[PubMed - indexed for MEDLINE]
20.

A retrospective review of antiemetic use for chemotherapy-induced nausea and vomiting in pediatric oncology patients at a tertiary care center.

Aseeri M, Mukhtar A, Al Khansa S, Elimam N, Jastaniah W.

J Oncol Pharm Pract. 2013 Jun;19(2):138-44. doi: 10.1177/1078155212457966. Epub 2012 Oct 3.

PMID:
23034405
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk